echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > AstraZeneca/Oxford new crown vaccine approved in Germany for people over 65

    AstraZeneca/Oxford new crown vaccine approved in Germany for people over 65

    • Last Update: 2021-03-22
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

        

    On March 5, foreign media reported that the new crown vaccine jointly developed by AstraZeneca and Oxford University has been approved in Germany for people over 65 years of age.
    Previously, the country chose not to authorize vaccinations for people over 65 years of age.

    The Vaccination Committee of the German Ministry of Health recommends that the interval between the first and second doses of the AstraZeneca/Oxford vaccine be extended up to 12 weeks.
    Studies have shown that extending the time between two vaccinations can increase the effectiveness of the vaccine.
    These research data were published in the preprint of The Lancet, and the report stated, “After the second injection, the longer the interval, the higher the effectiveness of the vaccine.
    The effectiveness of the vaccine with an interval of 12 weeks or longer between the two doses reached 82.
    4%.
    .
    "

    Earlier this year, the German "Business Daily" and "Bild" respectively reported that the AstraZeneca/Oxford vaccine is only 8% or less than 10% effective for people 65 years of age and older.
    AstraZeneca refuted German media reports that the AstraZeneca/Oxford cooperative vaccine is not effective for people over 65 years of age.
    In response, AstraZeneca stated that these reports were "completely false" and cited clinical data to emphasize the benefits of vaccines in this patient population.

    Both the European Medicines Agency (EMA) and the World Health Organization (WHO) recommend the use of AstraZeneca/Oxford vaccines for people over 65 years of age.

    A recent real-world study by the Department of Public Health of the United Kingdom (PHE) also found that the AstraZeneca/Oxford vaccine can significantly reduce the incidence of severe new crowns in the elderly.
    The main indicators of this real-world study include COVID-19-related hospitalizations and deaths among vaccinated people over 70 who have symptoms and confirmed SARS-CoV-2 infection by nucleic acid testing.
    The study found that a dose of AstraZeneca/Oxford vaccine protects from 60% to 73% of new crown symptoms after 4 weeks.
    The data also shows that in people over 80 years old, a dose of AstraZeneca/Oxford new crown vaccine or Pfizer/BioNTech vaccine is more than 80% effective in preventing new crown hospitalization 3 to 4 weeks after vaccination.

    German Health Minister Jens Spahn announced the committee’s decision last Thursday.
    He said that this measure is good news for the elderly waiting for the injection.
    They can now get vaccinated faster, and the authorities will soon issue regulations to implement it.
    .

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.
    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent Echemi's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.